亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials

医学 利拉鲁肽 艾塞那肽 内科学 胰高血糖素样肽1受体 2型糖尿病 肠促胰岛素 杜拉鲁肽 赛马鲁肽 胰高血糖素 糖尿病 利西塞纳泰德 胰高血糖素样肽-1 2型糖尿病 不利影响 内分泌学 胰岛素 低血糖 安慰剂 血糖性 二甲双胍 药理学 耐受性 随机对照试验 联合疗法 受体 兴奋剂
作者
Xiang Xue,Ren Z,A Zhang,Qian Yang,W Zhang,Liu F
出处
期刊:International Journal of Clinical Practice [Wiley]
卷期号:70 (8): 649-656 被引量:12
标识
DOI:10.1111/ijcp.12847
摘要

Background Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promising results in the treatment of type 2 diabetes. Herein, we compared the efficacy and safety of once-weekly GLP-1RAs with exenatide and liraglutide separately. Methods We systematically surveyed the pertinent literature using various databases. The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included. Our main end-points were control of glycaemia, body weight, hypoglycaemia and gastrointestinal adverse events (AEs). Results Our analysis included eight trials involving 5531 patients. Exenatide-long-acting release (LAR), dulaglutide and taspoglutide were more effective than twice-daily exenatide in reducing glycosylated haemoglobin A1c (HbA1c) and fasting blood glucose (FBG) levels and achieving HbA1c targets (< 7.0% and ≤ 6.5%). Liraglutide was as effective as dulaglutide and more effective than exenatide-LAR and albiglutide in controlling glycaemia. With regard to the effectiveness in decreasing body weight, exenatide-LAR, dulaglutide and taspoglutide were similar to exenatide whereas exenatide-LAR, dulaglutide and albiglutide were inferior to liraglutide. Once-weekly GLP-1RAs, exenatide and liraglutide resulted in a similar incidence of hypoglycaemia and of gastrointestinal, serious, or other AEs. Conclusions Once-weekly GLP-1RAs were more effective in controlling glycaemia and equally effective in decreasing body weight than twice-daily exenatide but were inferior to liraglutide in controlling these two parameters (dulaglutide was similar with liraglutide in controlling glycaemia). Once-weekly GLP-1RAs, exenatide and liraglutide had a similar risk of causing AEs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
星辰大海应助Wei采纳,获得10
9秒前
科研通AI2S应助科研通管家采纳,获得10
25秒前
科目三应助科研通管家采纳,获得10
25秒前
26秒前
Thermalwave完成签到 ,获得积分10
39秒前
492357816完成签到,获得积分10
40秒前
53秒前
1分钟前
研友_8oBpRZ发布了新的文献求助10
2分钟前
SOLOMON应助hjybaba7采纳,获得80
2分钟前
2分钟前
Wei发布了新的文献求助10
2分钟前
理化发布了新的文献求助10
2分钟前
传奇3应助理化采纳,获得10
2分钟前
Perry完成签到,获得积分10
3分钟前
研友_8oBpRZ完成签到,获得积分10
3分钟前
try完成签到,获得积分10
3分钟前
研友_8oBpRZ发布了新的文献求助10
3分钟前
3分钟前
Wei发布了新的文献求助10
4分钟前
Joseph完成签到,获得积分10
6分钟前
牧沛凝完成签到,获得积分10
7分钟前
秋雪瑶应助牧沛凝采纳,获得10
7分钟前
韩学冲完成签到 ,获得积分10
8分钟前
hjybaba7发布了新的文献求助10
8分钟前
9分钟前
大小可爱发布了新的文献求助10
9分钟前
hjybaba7完成签到,获得积分10
9分钟前
大小可爱完成签到,获得积分10
9分钟前
10分钟前
10分钟前
ddd完成签到 ,获得积分10
10分钟前
10分钟前
欣喜翠丝发布了新的文献求助30
10分钟前
超帅的龙猫完成签到,获得积分20
10分钟前
斯文败类应助科研通管家采纳,获得10
12分钟前
暴躁的寻云完成签到 ,获得积分10
13分钟前
SOLOMON举报小宋求助涉嫌违规
13分钟前
14分钟前
14分钟前
高分求助中
Manual of Clinical Microbiology, 4 Volume Set (ASM Books) 13th Edition 1000
Edestus (Chondrichthyes, Elasmobranchii) from the Upper Carboniferous of Xinjiang, China 500
Chinese-English Translation Lexicon Version 3.0 500
Electronic Structure Calculations and Structure-Property Relationships on Aromatic Nitro Compounds 500
マンネンタケ科植物由来メロテルペノイド類の網羅的全合成/Collective Synthesis of Meroterpenoids Derived from Ganoderma Family 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 440
Two-sample Mendelian randomization analysis reveals causal relationships between blood lipids and venous thromboembolism 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2380965
求助须知:如何正确求助?哪些是违规求助? 2088260
关于积分的说明 5244402
捐赠科研通 1815283
什么是DOI,文献DOI怎么找? 905736
版权声明 558834
科研通“疑难数据库(出版商)”最低求助积分说明 483664